Screener
Aquestive Therapeutics, Inc. AQST Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s gross margin?
- Aquestive Therapeutics, Inc. (AQST) reported gross margin of 67% in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s gross margin changed year-over-year?
- Aquestive Therapeutics, Inc.'s gross margin increased by 9.7% year-over-year, from 61.1% to 67%.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s gross margin?
- Over 4 years (2020 to 2025), Aquestive Therapeutics, Inc.'s gross margin has grown at a -5.0% compound annual growth rate (CAGR), from 71.7% to 58.3%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.
Ask your AI about Aquestive Therapeutics, Inc.'s gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude